Literature DB >> 21489712

The evolving role of radiation therapy in the management of malignant melanoma.

Niloufer Khan1, Mohammad K Khan, Alex Almasan, Arun D Singh, Roger Macklis.   

Abstract

The incidence of melanoma is rising in the United States, leading to an estimated 68,720 new diagnoses and 8,650 deaths annually. The natural history involves metastases to lymph nodes, lung, liver, brain, and often to other sites. Primary treatment for melanoma is surgical excision of the primary tumor and affected lymph nodes. The role of adjuvant or definitive radiation therapy in the treatment of melanoma remains controversial, because melanoma has traditionally been viewed as a prototypical radioresistant cancer. However, recent studies suggest that under certain clinical circumstances, there may be a significant role for radiation therapy in melanoma treatment. Stereotactic radiosurgery for brain metastases has shown effective local control. High dose per fraction radiation therapy has been associated with a lower rate of locoregional recurrence of sinonasal melanoma. Plaque brachytherapy has evolved into a promising alternative to enucleation at the expense of moderate reduction in visual acuity. Adjuvant radiation therapy following lymphadenectomy in node-positive melanoma prevents local and regional recurrence. The newer clinical data along with emerging radiobiological data indicate that radiotherapy is likely to play a greater role in melanoma management and should be considered as a treatment option.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21489712      PMCID: PMC3119033          DOI: 10.1016/j.ijrobp.2010.12.071

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  65 in total

1.  The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18.

Authors:  M Diener-West; J D Earle; S L Fine; B S Hawkins; C S Moy; S M Reynolds; A P Schachat; B R Straatsma
Journal:  Arch Ophthalmol       Date:  2001-07

2.  Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation.

Authors:  Daniel T Chang; Robert J Amdur; Christopher G Morris; William M Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-12       Impact factor: 7.038

Review 3.  Radiation therapy as primary and adjuvant treatment for local and regional melanoma.

Authors:  Lawrence B Berk
Journal:  Cancer Control       Date:  2008-07       Impact factor: 3.302

Review 4.  Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma.

Authors:  Graham Stevens; Michael J McKay
Journal:  Lancet Oncol       Date:  2006-07       Impact factor: 41.316

5.  Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells.

Authors:  K Satyamoorthy; N H Chehab; M J Waterman; M C Lien; W S El-Deiry; M Herlyn; T D Halazonetis
Journal:  Cell Growth Differ       Date:  2000-09

6.  A comparison of survival rates for treatment of melanoma metastatic to the brain.

Authors:  Anne Stone; Jay Cooper; Karen L Koenig; John G Golfinos; Ruth Oratz
Journal:  Cancer Invest       Date:  2004       Impact factor: 2.176

7.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Authors:  James Tsai; John T Lee; Weiru Wang; Jiazhong Zhang; Hanna Cho; Shumeye Mamo; Ryan Bremer; Sam Gillette; Jun Kong; Nikolas K Haass; Katrin Sproesser; Ling Li; Keiran S M Smalley; Daniel Fong; Yong-Liang Zhu; Adhirai Marimuthu; Hoa Nguyen; Billy Lam; Jennifer Liu; Ivana Cheung; Julie Rice; Yoshihisa Suzuki; Catherine Luu; Calvin Settachatgul; Rafe Shellooe; John Cantwell; Sung-Hou Kim; Joseph Schlessinger; Kam Y J Zhang; Brian L West; Ben Powell; Gaston Habets; Chao Zhang; Prabha N Ibrahim; Peter Hirth; Dean R Artis; Meenhard Herlyn; Gideon Bollag
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

8.  Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.

Authors:  C Nogueira; K-H Kim; H Sung; K H T Paraiso; J-H Dannenberg; M Bosenberg; L Chin; M Kim
Journal:  Oncogene       Date:  2010-08-16       Impact factor: 9.867

9.  Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases.

Authors:  Ugur Selek; Eric L Chang; Samuel J Hassenbusch; Almon S Shiu; Frederick F Lang; Pamela Allen; Jeffrey Weinberg; Raymond Sawaya; Moshe H Maor
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

10.  The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region.

Authors:  Jonathan M Owens; Dianna B Roberts; Jeffrey N Myers
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2003-08
View more
  23 in total

Review 1.  Current treatment of locoregional recurrence of melanoma.

Authors:  Malcolm Hart Squires; Keith A Delman
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

Review 2.  Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review.

Authors:  Sharad Goyal; Ann W Silk; Sibo Tian; Janice Mehnert; Shabbar Danish; Sinthu Ranjan; Howard L Kaufman
Journal:  JAMA Oncol       Date:  2015-08       Impact factor: 31.777

3.  Stereotactic ablative body radiotherapy (SABR) for effective palliation of metastases: factors affecting local control.

Authors:  Pretesh R Patel; John Kirkpatrick; Joseph K Salama; John Nelson; Gloria Broadwater; Karen Allen; Robert Clough; Fang-Fang Yin; Zhiheng Wang; Zheng Chang; Christopher Kelsey; A Paiman Ghafoori
Journal:  J Radiosurg SBRT       Date:  2014

Review 4.  Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.

Authors:  Kirtesh R Patel; David H Lawson; Ragini R Kudchadkar; Bradley C Carthon; Daniel E Oliver; Derick Okwan-Duodu; Rafi Ahmed; Mohammad K Khan
Journal:  Neuro Oncol       Date:  2015-05-25       Impact factor: 12.300

5.  The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis.

Authors:  Hasan H Danish; Kirtesh R Patel; Jeffrey M Switchenko; Theresa W Gillespie; Jaymin Jhaveri; Mudit Chowdhary; Mustafa Abugideiri; Keith A Delman; David H Lawson; Mohammad K Khan
Journal:  Melanoma Res       Date:  2016-12       Impact factor: 3.599

6.  SLUG silencing increases radiosensitivity of melanoma cells in vitro.

Authors:  Chiara Arienti; Anna Tesei; Silvia Carloni; Paola Ulivi; Antonino Romeo; Giulia Ghigi; Enrico Menghi; Anna Sarnelli; Elisabetta Parisi; Rosella Silvestrini; Wainer Zoli
Journal:  Cell Oncol (Dordr)       Date:  2012-12-19       Impact factor: 6.730

Review 7.  The role of radiotherapy in the management of sinonasal melanoma and its impact on patients and healthcare professionals.

Authors:  A Moore
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-12-24       Impact factor: 2.503

8.  Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report.

Authors:  Jee Min Lee; Urvi N Mehta; Ly H Dsouza; Beverly Ashleigh Guadagnolo; Deborah L Sanders; Kevin B Kim
Journal:  Melanoma Res       Date:  2013-04       Impact factor: 3.599

9.  Development of DNA damage response signaling biomarkers using automated, quantitative image analysis.

Authors:  Nana Nikolaishvilli-Feinberg; Stephanie M Cohen; Bentley Midkiff; Yingchun Zhou; Mark Olorvida; Joseph G Ibrahim; Bernard Omolo; Janiel M Shields; Nancy E Thomas; Pamela A Groben; William K Kaufmann; C Ryan Miller
Journal:  J Histochem Cytochem       Date:  2013-12-05       Impact factor: 2.479

10.  Malignant melanoma and radiotherapy: past myths, excellent local control in 146 studied lesions at Georgetown University, and improving future management.

Authors:  Pooya Jahanshahi; Nadim Nasr; Keith Unger; Ali Batouli; Gregory J Gagnon
Journal:  Front Oncol       Date:  2012-11-15       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.